Open AccessGold Nanorods Targeted to Delta Opioid Receptor: Plasmon-Resonant Contrast and Photothermal Agents
Author(s) -
Kvar C. L. Black,
Nathaniel D. Kirkpatrick,
Timothy S. Troutman,
Liping Xu,
Josef Vágner,
Robert J. Gillies,
Jennifer K. Barton,
Urs Utzinger,
Marek Romanowski
Publication year - 2008
Publication title -
molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.815
H-Index - 60
eISSN - 1536-0121
pISSN - 1535-3508
DOI - 10.2310/7290.2008.0007
Subject(s) - nanorod , linker , ligand (biochemistry) , receptor , in vivo , chemistry , biophysics , cancer research , microbiology and biotechnology , materials science , nanotechnology , biology , biochemistry , computer science , operating system
Molecularly targeted gold nanorods were investigated for applications in both diagnostic imaging and disease treatment with cellular resolution. The nanorods were tested in two genetically engineered cell lines derived from the human colon carcinoma HCT-116, a model for studying ligand-receptor interactions. One of these lines was modified to express delta opioid receptor (δOR) and green fluorescent protein, whereas the other was receptor free and expressed a red fluorescent protein, to serve as the control. Deltorphin, a high-affinity ligand for δOR, was stably attached to the gold nanorods through a thiol-terminated linker. In a mixed population of cells, we demonstrated selective imaging and destruction of receptor-expressing cells while sparing those cells that did not express the receptor. The molecularly targeted nanorods can be used as an in vitro ligand-binding and cytotoxic treatment assay platform and could potentially be applied in vivo for diagnostic and therapeutic purposes with endoscopic technology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom